By: Jennifer Barrett From: specialtypharmacytimes.com Margetuximab, an investigational monoclonal antibody, improved progression-free survival (PFS) when used in combination with chemotherapy in patients with human epidermal growth factor receptor 2- (HER2) positive metastatic breast cancer, according to new data from a pivotal phase 3 trial. The SOPHIA study, which enrolled 536 patients, evaluated margetuximab in combination with chemotherapy compared with trastuzumab …
Novel App Uses AI to Guide, Support Cancer Patients
From: rh.gatech.edu Artificial Intelligence is helping to guide and support some 50 breast cancer patients in rural Georgia through a novel mobile application that gives them personalized recommendations on everything from side effects to insurance. The app, called MyPath, adapts to each stage in a patient’s cancer journey. So the information available on the app – which runs on a …
More than Half a Million Breast Cancer Deaths Averted in the U.S. Over Three Decades
Source: Wiley Research News From: prnewswire.com Latest U.S. estimates indicate that since 1989, hundreds of thousands of women’s lives have been saved by mammography and improvements in breast cancer treatment. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings point to progress made in early detection and management of breast cancer. Screening mammography for …
Why Don’t We Advocate for Our Own Health Issues – Even Cancer
View PostNew machine learning method could spare some women from unnecessary breast surgery
Source: Dartmouth-Hitchcock Medical Center From: eurekalert.org Atypical ductal hyperplasia (ADH) is a breast lesion associated with a four- to five-fold increase in the risk of breast cancer. ADH is primarily found using mammography and identified on core needle biopsy. Despite multiple passes of the lesion during biopsy, only portions of the lesions are sampled. Other variable factors influence sampling and …
High costs of breast cancer-associated lymphedema can ‘cripple’ patients financially
From: healio.com Individuals with breast cancer continue to face high health care costs years after a diagnosis, according to study findings published in Journal of Supportive Care and Cancer. The problem is particularly apparent among those with breast cancer-associated lymphedema. Results showed annual out-of-pocket costs of $2,306 for those with lymphedema vs. $1,090 for those without lymphedema — a 112% …
Cancer and The Toxic Workplace
View PostHypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer
From: thelancet.com A randomised, non-inferiority, open-label, phase 3 trial Background To our knowledge, no randomised study has compared postmastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy in patients with breast cancer. This study aimed to determine whether a 3-week schedule of postmastectomy hypofractionated radiotherapy is as efficacious and safe as a 5-week schedule of conventional fractionated radiotherapy. Methods This randomised, non-inferiority, …
What to know about multifocal breast cancer
From: Jamie Eske From: medicalnewstoday.com Multifocal breast cancer is a form of breast cancer in which multiple tumors arise in the same area of the breast. There are many types of breast cancer. The type and characteristics, including the number of tumors and where they are, can affect a person’s treatment and long-term outlook. This article covers information about multifocal …